相似文献
1
Heparin-Induced Thrombocytopenia in Severe COVID-19.重症新型冠状病毒肺炎中的肝素诱导的血小板减少症
Circulation. 2020 Nov 10;142(19):1875-1877. doi: 10.1161/CIRCULATIONAHA.120.049015. Epub 2020 Sep 29.
2
Heparin-Induced Thrombocytopenia in COVID-19.新型冠状病毒肺炎中的肝素诱导的血小板减少症
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620944091. doi: 10.1177/2324709620944091.
3
Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019.阿加曲班治疗1例2019冠状病毒病患者的肝素诱导的血小板减少症
J Thromb Thrombolysis. 2020 Nov;50(4):1012-1014. doi: 10.1007/s11239-020-02248-8. Epub 2020 Aug 11.
4
Establishment and Management of Mechanical Circulatory Support During the COVID-19 Pandemic.新型冠状病毒肺炎大流行期间机械循环支持的建立与管理
Circulation. 2020 Jul 7;142(1):10-13. doi: 10.1161/CIRCULATIONAHA.120.047415. Epub 2020 May 4.
5
Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan.武汉48例重症新型冠状病毒肺炎患者下肢深静脉血栓形成的极高发生率
Circulation. 2020 Jul 14;142(2):181-183. doi: 10.1161/CIRCULATIONAHA.120.047407. Epub 2020 May 15.
6
Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure.新型冠状病毒（COVID-19）呼吸衰竭的高压氧治疗
Med Gas Res. 2020 Apr-Jun;10(2):61-62. doi: 10.4103/2045-9912.282177.
7
Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy.接受肝素治疗的COVID-19患者中抗肝素-PF4复合物抗体的检测。
Blood Transfus. 2020 Jul;18(4):328. doi: 10.2450/2020.0164-20.
8
Venous thromboembolism in non-critically ill patients with COVID-19 infection.COVID-19 感染非危重症患者的静脉血栓栓塞症。
Thromb Res. 2020 Sep;193:166-169. doi: 10.1016/j.thromres.2020.07.033. Epub 2020 Jul 17.
9
Mechanisms involved in the development of thrombocytopenia in patients with COVID-19.与 COVID-19 患者血小板减少症发展相关的机制。
Thromb Res. 2020 Sep;193:110-115. doi: 10.1016/j.thromres.2020.06.008. Epub 2020 Jun 5.
10
Severe COVID-19 infection associated with endothelial activation.严重的2019冠状病毒病感染与内皮细胞激活有关。
Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.
引用本文的文献
1
Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19.针对重症 COVID-19 中刺突蛋白受体结合域的促血栓形成抗体。
Blood. 2025 Feb 6;145(6):635-647. doi: 10.1182/blood.2024025010.
2
The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.Ad26.COV2.S疫苗接种后刺突蛋白的生物分布不太可能在疫苗诱导的免疫性血栓性血小板减少症中起作用。
Vaccines (Basel). 2024 May 20;12(5):559. doi: 10.3390/vaccines12050559.
3
Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in Rabbits.与兔肌肉注射疫苗相比，静脉注射Ad26.COV2.S不会诱导血小板减少或血栓形成事件，也不会影响血液中SARS-CoV-2刺突蛋白的生物利用度。
Vaccines (Basel). 2023 Nov 30;11(12):1792. doi: 10.3390/vaccines11121792.
4
COVID-19 and cardiovascular disease in patients with chronic kidney disease.COVID-19 与慢性肾脏病患者的心血管疾病。
Nephrol Dial Transplant. 2024 Jan 31;39(2):177-189. doi: 10.1093/ndt/gfad170.
5
Significance of heparin induced thrombocytopenia (HIT) in COVID-19: a systematic review and meta-analysis.肝素诱导的血小板减少症（HIT）在 COVID-19 中的意义：系统评价和荟萃分析。
J Thromb Thrombolysis. 2023 Aug;56(2):241-252. doi: 10.1007/s11239-023-02827-5. Epub 2023 May 23.
6
Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.新冠病毒感染与镰状细胞病中的血栓炎症：同一枚硬币的两面
Biomedicines. 2023 Jan 25;11(2):338. doi: 10.3390/biomedicines11020338.
7
An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection.血管紧张素转换酶2的结构/功能、多态性及其在2019冠状病毒病病理生理学中的双重性质的最新进展：对与严重急性呼吸综合征冠状病毒感染相关的血管和凝血疾病的影响。
Front Microbiol. 2022 Nov 28;13:1042200. doi: 10.3389/fmicb.2022.1042200. eCollection 2022.
8
Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study.新冠重症患者中依诺肝素与普通肝素的标准剂量对比：一项多中心倾向评分匹配研究
Thromb J. 2022 Dec 8;20(1):74. doi: 10.1186/s12959-022-00432-9.
9
Neutrophils: As a Key Bridge between Inflammation and Thrombosis.中性粒细胞：炎症与血栓形成之间的关键桥梁
Evid Based Complement Alternat Med. 2022 Nov 9;2022:1151910. doi: 10.1155/2022/1151910. eCollection 2022.
10
Subcutaneous Enoxaparin for Systemic Anticoagulation of COVID-19 Patients During Extracorporeal Life Support.皮下注射依诺肝素用于体外生命支持期间COVID-19患者的全身抗凝
Front Med (Lausanne). 2022 Jul 11;9:879425. doi: 10.3389/fmed.2022.879425. eCollection 2022.
本文引用的文献
1
Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan.武汉48例重症新型冠状病毒肺炎患者下肢深静脉血栓形成的极高发生率
Circulation. 2020 Jul 14;142(2):181-183. doi: 10.1161/CIRCULATIONAHA.120.047407. Epub 2020 May 15.
2
Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis.血小板与成年患者体外膜肺氧合：系统评价和荟萃分析。
Intensive Care Med. 2020 Jun;46(6):1154-1169. doi: 10.1007/s00134-020-06031-4. Epub 2020 Apr 23.
3
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
4
Prevalence and Risk Factors for Thrombotic Complications Following Venovenous Extracorporeal Membrane Oxygenation: A CT Scan Study.静脉-静脉体外膜肺氧合后血栓并发症的患病率和危险因素：一项 CT 扫描研究。
Crit Care Med. 2020 Feb;48(2):192-199. doi: 10.1097/CCM.0000000000004129.
5
Heparin-induced thrombocytopenia in critically ill patients.危重症患者的肝素诱导血小板减少症。
Semin Thromb Hemost. 2015 Feb;41(1):49-60. doi: 10.1055/s-0034-1398381. Epub 2015 Jan 15.
Zotero 插件